

عني ن ص ت ل ا ل ا م ع ا ة ي خ ي ر ا ت ل ا ي ئ ا و د ل ا



MERGERSCORP

،ةيضاماللةلقلل دوقعلا في يملع بعالك ةيدنهلا ةيودألا ةعانص تزرب
ءانء عيمج في ةسينجلا ةيودألا يجتنم ربكأ نم ةدحاو تحبصأ ثيح
،ةيدنهلا ةيودألا لاجم في ةلئاه أو من ةيدنهلا ةيودألا ةراجت تدش .ملاعلا
دح لىل ةيودلا ةيولحلا قواسألا في اءوحو قاطن عيسوت لىل ةيودألا
ءاوس .

ةريبك ةعومجم ءوحو ببسب ةلئاه ةاينك مإب يدينهلا ةيودألا عاطق عتمتي
ةفلكل ةلثيح نم ةلاعلا ةيولحلا ةارءوق ةرهملل نيينهملل نم
ةيوقلا ةيتحتل ةيولحلا مهاسء امك .قلاطنل ةعساو ةيجءا ةلءارءوقلا
دينهلا نضتحت .ةيودألا لاجم في اءحاجن في ءالبلل في ريوطءلا ءاىءا
راطإ اءيءلو ،ةريهشلا ةيولحلا ةيولحلا ءاسسؤملا نم ءيءءلا
ءوحو ريءاعم ءافءسا نامضل يوق يميظنء .

ءوقو .ةريءألا ءاونسلل في ةريبك ءازاجن ةيدينهلا ةيودألا ةعانص ءققح
،ةسينجلا ةيودألا نم ةعساو ةعومجم عيولحلا ريوطء في ءكءرشلل ءحجن
.ملاعلا ءوسم لىل ءءامو ةفلكل ءروسيم ةيولحلا ةيولحلا لءع ام
في أمسءا ءرود ةيدينهلا ةيودألا فيلءك ءمءت لىل ءرءوقلا ءبعءل ءوقو
في ءمهاسملا نع ءلصف ،ةيولحلا لءول ءيولحلا ةيولحلا لءولح ريءوفء
ءمءءملا لءولح في ءيولحلا ءيولحلا ءلصف .

أن نم ءوحو ءيولحلا ءيولحلا ءيولحلا ءيولحلا ءيولحلا ءيولحلا
ءانء عيمج في ءءلبلل لىل ءيولحلا ءيولحلا ءيولحلا ءيولحلا
ءالء نم ءءايللم قاطن عيسوتب ةيدينهلا ءيولحلا ءكءرشلل ءمء .ملاعلا
ءلءم ءسيمي امم ،ءءلبلل ءلءم في ءاىءا ءكءرشلل ءيولحلا ءيولحلا
ءفءلءم قواسألا ءءمءل ءاىءا ءلءم ءيولحلا .

ققح لءب ،ببسب ءيولحلا ءيولحلا لىل ءيولحلا ءيولحلا ءيولحلا
نم ءيولحلا ءمءل ءوقو .ءيولحلا ريوطءلا ءيولحلا لاجم في ءعساو ءاوطء ءضيأ
ةيولحلا ءاىءا لاجم في ءريبك ءارامء ءسءاب ءيدينهلا ءكءرشلل
ءلءل ءيولحلا ءيولحلا لىل ءيولحلا ءيولحلا ءيولحلا ،ةركءبملا
زءع امم ،ضارمألا ءلءم ءرولءم ريولحلا لىل ءلءل ءيولحلا .ةيولحلا
ءيولحلا راءءل ءكءرشلل ءيولحلا ءيولحلا .

ءمء ءمء

ءءاوي هو .دينهلا في ءيولحلا ءرولءم عقي ءايسنءل ءءءم ءيولحلا ءكءرشلل
ءلءم 30 نم رءكأ في ءمءءو ،ءيسأ في ءءارءل ءيولحلا ءيولحلا ءكءرشلل نم
ءيولحلا ءيولحلا نيين ءوارةء ءيولحلا ءيولحلا نم ءعونءم ءعومجم اءيءلو
ءانوءملا ءيولحلا ءيولحلا ءيولحلا ءيولحلا ءيولحلا ءيولحلا
ءلاعلا ءيولحلا ءيولحلا .

رهءشء امك ،ريوطءلا ءيولحلا لاجم في ءيولحلا ءيولحلا ءكءرشلل رهءشء
نيين ءيولحلا ءكءرشلل مءءلء .ءلءوقءم راعسأبو ءوحو ءيولحلا ءيولحلا
ءاىءل ءءاىء عيسوءملاعلا ءيولحلا ءيولحلا ءيولحلا لىل لءولء

TARGET PRICE

\$1,050,000,000

GROSS REVENUE

\$306,500,000

EBITDA

\$87,500,000

BUSINESS TYPE

Pharma

COMPETITION

Lupin Limited, Cadila
Healthcare, Torrent
Pharmaceuticals,
Aurobindo, Pharma,
Biocon, Glenmark
Pharmaceuticals, Alkem
Laboratories

SUPPORT & TRAINING

ءرهش 24

REASON FOR SELLING

ءنء

COUNTRY

دينهلا

BUSINESS ID

L#20240605

اهتاسراممو ةركت بملا اهتاجت نم لال خ نم سانلا ةايح ىلع ي باجاي إري ثأت
ةمادت سمل

تامالعل تاذ ةيودألا مطعم عي نصت ب ي لال حا ل تقولا ي ة كرشلا موقت
اهنكلو ، ةصاخلا ةيراجتلا اهتامال ع قيوست ب موقت الو ، ةصاخلا ةيراجتلا
، تالوس بك ، بارش) ةعئاشلا ةينالديصلال لال كشألا مطعم عي نصت ب موقت
(ل ل ل ا ح ، تارصحت سم ، ق ي ح اسم ، صارقأ

ةيس يئرلا طاقنلا

1. تانوكملاو ةسي نجللا ةيودألا قيوستو عي نصت ىلع زكرت
ةصصخملا ةينالديصلال تامدخللاو (APIs) ةطشنلا ةينالديصلال
2. فل تخم ي طغت ي تلل ا تاجت نملا نم ةعونتم ةظفحم ةكرشلا ككلمت
ةيودملا ةيوعوألاو بلقلل صارمأ كلذ ي ف ام ب ، ةيجالعل تائفلا
ماروألاو ةيدلجلل صارمألاو ي مضمهلا زاهجللاو باصعألاو
3. م ل ا ل ل و ح ة ل و د 30 ن م ر ث ك أ ي ف ل م ع ت و ي م ل ا ع ر و ض ح .
4. ن م ر ي ب ك ء ز ج ر ا م ث ت س ا و ، ر ي و ط ت ل ا و ث ح ب ل ا ى ل ع ي و ق ل ل ز ي ك ر ت ل ا
ر ي و ط ت ل ل ا و ث ح ب ل ا ة ط ش ن ا ن ي ف ا ه ت ا د ا ر ي ا
5. ر ي و ط ت ى ل ع ن و ل م ع ي ن ي ذ ل ا ن ي ث ح ا ب ل ا و ء ا م ل ل ع ل ا ن م ص ص خ م ق ي ر ف
ةي ل ل ا ح ل ل ا ت ا ب ي ك ر ت ل ل ن ي س ح ت و ة د ي د ج ة ي ة ا و د ت ا ب ي ك ر ت
6. ت ا ع ا د ي ا ل ا ن م د ي د ع ل ل ع م ، ة د ي د ج ل ل ا ت ا ج ت ن م ل ا ن م ة ي و ق ة و م ج م
ن ا د ل ب ل ا ف ل ت خ م ي ف ت ا ق ا و م ل ا و
7. ة ي م ي ط ن ت ل ا ر ي ا ع م ل ل ل ا ث ت م ا ل ا و ة د و ج ل ل ا ى ل ع ز ي ك ر ت ب ف و ر ع م
ة ي ل ل و د ل ا
8. م ز ت ل ت ي ت ل ا و ، ا ه ج ر ا خ و د ن ه ل ا ي ف ع ي ن ص ت ل ا ت ا ش ن م ن م د ي د ع ل ل ا
ة د ي د ج ل ل ع ي ن ص ت ل ا ت ا س ر ا م م ت ا د ا ش ر ا ب (GMP).
9. ن م ة س ي ن ج ل ل ا ت ا ر ا د ص ا ل ا ق ي و س ت و ق ا ل ط ا ي ف ح ا ج ن ل ا ب ل ف ا ح ل ج س
أ ي م ل ا ع ة ج ئ ا ر ل ا ة ي و د أ ل ا
10. ت ا ئ ي ز ج ى ل ل ا ل و ص و ل ل ة د ئ ا ر ل ا ة ي و د أ ل ا ت ا ك ر ش ع م ن و ا ع ت و ت ا ك ا ر ش ة م ا ق ا
ة د ي د ج ق ا و س أ و

بولطم KYC، POF

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM